Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDSY-1240 in Participants With Hematologic Malignancies and Advanced Solid Tumors
NCT07899632Phase 2Not yet recruiting
- Sponsor
- Medsyn Biopharma
- Start
- Nov 2026
- Primary completion
- Aug 2029
01
Overview
A Phase 2 trial of MDSY-1240 in triple-negative breast cancer (TNBC), gastric cancer (GC), ovarian cancer, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), sponsored by Medsyn Biopharma. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
MDSY-1240
03
Conditions
triple-negative breast cancer (TNBC)gastric cancer (GC)ovarian cancerhead and neck squamous cell carcinoma (HNSCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07899632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07899632.